Furthermore, over a median follow-up of 24 months, the use of SGLT2 inhibitors was associated with a significant reduction in the incidence of major adverse cardiovascular events, all-cause mortality, and hospitalization for heart failure compared to those who did not receive this therapy [40]. Here, SLC5A2 is linked to heart failure.